Leerink Partners analyst Lili (Aurélie) Nsongo has maintained their bullish stance on RFM stock, giving a Buy rating on July 1.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lili (Aurélie) Nsongo has given her Buy rating due to a combination of factors surrounding Sensorion SAS’s promising developments in their gene therapy program for hearing loss. The initial data from the Phase 1/2 Audiogene study of SENS-501 showed mixed results, with one out of three patients in Cohort 1 demonstrating significant improvements in hearing thresholds and auditory behavior. This positive outcome in Patient 3, who showed meaningful auditory improvements, suggests potential efficacy of the treatment at higher doses.
Furthermore, the ongoing dose-escalation study, which has shown no safety concerns so far, is expected to provide more comprehensive data as Cohort 2 progresses. The anticipation of further positive results and the strategic plan to expand the study at the optimal dose level contribute to the optimistic outlook. These factors, combined with the competitive landscape where Sensorion’s program is advancing alongside other promising studies, underpin Nsongo’s Buy rating for the stock.
In another report released on July 1, Chardan Capital also initiated coverage with a Buy rating on the stock with a €1.00 price target.
RFM’s price has also changed dramatically for the past six months – from EUR0.592 to EUR0.271, which is a -54.22% drop .